HRP20240858T1 - Kristal spoja oksazola - Google Patents
Kristal spoja oksazola Download PDFInfo
- Publication number
- HRP20240858T1 HRP20240858T1 HRP20240858TT HRP20240858T HRP20240858T1 HR P20240858 T1 HRP20240858 T1 HR P20240858T1 HR P20240858T T HRP20240858T T HR P20240858TT HR P20240858 T HRP20240858 T HR P20240858T HR P20240858 T1 HRP20240858 T1 HR P20240858T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystal
- infrared absorption
- measured
- peaks
- rays
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims 14
- -1 Oxazole compound Chemical class 0.000 title claims 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000000862 absorption spectrum Methods 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018072717 | 2018-04-04 | ||
| PCT/JP2019/014730 WO2019194211A1 (en) | 2018-04-04 | 2019-04-03 | Oxazole compound crystal |
| EP19718465.8A EP3774745B1 (en) | 2018-04-04 | 2019-04-03 | Oxazole compound crystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240858T1 true HRP20240858T1 (hr) | 2024-10-11 |
Family
ID=66223774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240858TT HRP20240858T1 (hr) | 2018-04-04 | 2019-04-03 | Kristal spoja oksazola |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11414391B2 (enExample) |
| EP (2) | EP4400167A3 (enExample) |
| JP (4) | JP7326295B2 (enExample) |
| KR (2) | KR102764726B1 (enExample) |
| CN (1) | CN111902402A (enExample) |
| AU (2) | AU2019249562B2 (enExample) |
| BR (1) | BR112020019377A2 (enExample) |
| CA (1) | CA3095866A1 (enExample) |
| DK (1) | DK3774745T3 (enExample) |
| EA (1) | EA202092393A1 (enExample) |
| ES (1) | ES2982586T3 (enExample) |
| FI (1) | FI3774745T3 (enExample) |
| HR (1) | HRP20240858T1 (enExample) |
| HU (1) | HUE066793T2 (enExample) |
| IL (2) | IL277730B2 (enExample) |
| LT (1) | LT3774745T (enExample) |
| MX (1) | MX2020010435A (enExample) |
| MY (1) | MY202406A (enExample) |
| PH (1) | PH12020551605A1 (enExample) |
| PL (1) | PL3774745T3 (enExample) |
| PT (1) | PT3774745T (enExample) |
| SG (1) | SG11202009564TA (enExample) |
| SI (1) | SI3774745T1 (enExample) |
| TW (2) | TWI860993B (enExample) |
| WO (1) | WO2019194211A1 (enExample) |
| ZA (1) | ZA202006134B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3774745T3 (da) * | 2018-04-04 | 2024-06-17 | Otsuka Pharma Co Ltd | Krystal af en oxazolforbindelse |
| EP4501324A1 (en) | 2022-03-25 | 2025-02-05 | Otsuka Pharmaceutical Co., Ltd. | Wound treatment composition |
| CN115887463A (zh) * | 2022-12-27 | 2023-04-04 | 瑞石生物医药有限公司 | 一种含环酰胺化合物的药物组合物 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330639B (en) * | 2005-11-15 | 2010-09-21 | Otsuka Pharma Co Ltd | Oxazole compound and pharmaceutical composition |
| WO2014034958A1 (en) * | 2012-08-30 | 2014-03-06 | Otsuka Pharmaceutical Co., Ltd. | Method for producing oxazole compound |
| TWI726027B (zh) | 2015-12-28 | 2021-05-01 | 日商大塚製藥股份有限公司 | 軟膏 |
| DK3774745T3 (da) * | 2018-04-04 | 2024-06-17 | Otsuka Pharma Co Ltd | Krystal af en oxazolforbindelse |
-
2019
- 2019-04-03 DK DK19718465.8T patent/DK3774745T3/da active
- 2019-04-03 SI SI201930776T patent/SI3774745T1/sl unknown
- 2019-04-03 PL PL19718465.8T patent/PL3774745T3/pl unknown
- 2019-04-03 KR KR1020207031251A patent/KR102764726B1/ko active Active
- 2019-04-03 CN CN201980022064.2A patent/CN111902402A/zh active Pending
- 2019-04-03 EP EP24172132.3A patent/EP4400167A3/en active Pending
- 2019-04-03 ES ES19718465T patent/ES2982586T3/es active Active
- 2019-04-03 IL IL277730A patent/IL277730B2/en unknown
- 2019-04-03 JP JP2020539109A patent/JP7326295B2/ja active Active
- 2019-04-03 CA CA3095866A patent/CA3095866A1/en active Pending
- 2019-04-03 SG SG11202009564TA patent/SG11202009564TA/en unknown
- 2019-04-03 IL IL315425A patent/IL315425A/en unknown
- 2019-04-03 TW TW108111946A patent/TWI860993B/zh active
- 2019-04-03 US US17/044,892 patent/US11414391B2/en active Active
- 2019-04-03 EP EP19718465.8A patent/EP3774745B1/en active Active
- 2019-04-03 LT LTEPPCT/JP2019/014730T patent/LT3774745T/lt unknown
- 2019-04-03 MY MYPI2020005118A patent/MY202406A/en unknown
- 2019-04-03 PT PT197184658T patent/PT3774745T/pt unknown
- 2019-04-03 TW TW113146840A patent/TW202515853A/zh unknown
- 2019-04-03 KR KR1020257003493A patent/KR20250022254A/ko active Pending
- 2019-04-03 FI FIEP19718465.8T patent/FI3774745T3/fi active
- 2019-04-03 WO PCT/JP2019/014730 patent/WO2019194211A1/en not_active Ceased
- 2019-04-03 AU AU2019249562A patent/AU2019249562B2/en active Active
- 2019-04-03 EA EA202092393A patent/EA202092393A1/ru unknown
- 2019-04-03 MX MX2020010435A patent/MX2020010435A/es unknown
- 2019-04-03 HU HUE19718465A patent/HUE066793T2/hu unknown
- 2019-04-03 BR BR112020019377-1A patent/BR112020019377A2/pt unknown
- 2019-04-03 HR HRP20240858TT patent/HRP20240858T1/hr unknown
-
2020
- 2020-09-30 PH PH12020551605A patent/PH12020551605A1/en unknown
- 2020-10-02 ZA ZA2020/06134A patent/ZA202006134B/en unknown
-
2021
- 2021-12-03 JP JP2021196978A patent/JP2022037040A/ja active Pending
-
2022
- 2022-07-07 US US17/859,675 patent/US11840512B2/en active Active
-
2023
- 2023-10-03 JP JP2023171778A patent/JP2024001115A/ja active Pending
- 2023-10-31 US US18/498,894 patent/US20240076275A1/en not_active Abandoned
-
2024
- 2024-09-24 AU AU2024220015A patent/AU2024220015A1/en active Pending
-
2025
- 2025-03-27 US US19/092,743 patent/US20250250243A1/en active Pending
- 2025-06-04 JP JP2025093100A patent/JP2025128238A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240858T1 (hr) | Kristal spoja oksazola | |
| HRP20210507T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku | |
| MX373612B (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| HRP20211834T1 (hr) | Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola | |
| JP2014526498A5 (enExample) | ||
| AR077242A1 (es) | Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades. | |
| FI2882444T3 (fi) | Mikrohuokoinen zirkoniumsilikaatti hyperkalemian hoitoon | |
| HRP20120662T1 (hr) | Termodinamički stabilni oblik bay 43-9006 tosilata | |
| RU2017141763A (ru) | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| WO2014136282A8 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
| JP2022037040A5 (enExample) | ||
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| WO2019235725A8 (ko) | 유기 광전자 소자용 화합물，유기 광전자 소자용 조성물，유기광전자 소자 및 표시 장치 | |
| HRP20251307T1 (hr) | Kristalni oblik trietilentetramin tetrahidroklorida i njegova farmaceutska upotreba | |
| Golovnev et al. | The cis–trans isomer transformation, spectroscopic and thermal properties of Li, Na, K 1, 3-diethyl-2-thiobarbiturate complexes | |
| Xu et al. | Evaluation of andrographolide-based analogs derived from Andrographis paniculata against Mythimna separata Walker and Tetranychus cinnabarinus Boisduval | |
| JP2021517111A5 (enExample) | ||
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| WO2014159061A3 (en) | Benzo-fused heterocyclic derivatives useful as agonists of gpr120 | |
| Ye et al. | Chemical constituents of Ziziphora clinopodioides a |